Trial Profile
Long-term Observational Study in Patients Under Anti-retroviral Combination Therapy Who Were Switched From Protease Inhibitors or Other NNRTI to Viramune(R) Plus Two Nucleoside Reverse Transcriptase Inhibitors (NRTI) for Reasons of Therapy. (Long-Term Switch)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Nevirapine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 22 Jul 2014 New trial record